ClinVar Miner

Submissions for variant NC_000018.9:g.(48556994_48573289)_48573471dup

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002510378 SCV002819609 likely pathogenic Juvenile polyposis syndrome 2022-12-16 criteria provided, single submitter clinical testing Variant summary: The variant identified by MLPA or other technology involves the duplication of partial exon 2 in the SMAD4 gene. A presumed nomenclature of c.(-128+1_-127-1)_55dup has been designated for the purposes of this classification. It has been assumed that this is a tandem duplication in direct orientation (Richardson_GIM_2018, Newman_AJHG_2015). Although exact breakpoints of this duplication are not known, it is expected to result in a frameshift duplication change in the SMAD4 gene. The variant was absent in 21694 control chromosomes (gnomAD SVs, Structural Variants dataset). To our knowledge, no occurrence of c.(-128+1_-127-1)_55dup in individuals affected with Juvenile Polyposis Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.